Janssen Biotech Inc, a unit of Johnson & Johnson, filed a lawsuit to block a copy of its blockbuster rheumatoid arthritis drug Remicade made by South Korea’s Samsung Bioepis Co Ltd from being sold in the United States, according to a Reuters report.
In a suit filed to the US District Court of New Jersey, Janssen Biotech is seeking a preliminary or permanent injunction to block Samsung Bioepis’ biosimilar of Remicade from sale and argues the South Korean company violated three of its patents.
Remicade is Johnson & Johnson’s biggest selling drug, with US sales of about $5 billion a year, Reuters reported.
“We have filed a lawsuit against Samsung to investigate whether their biosimilar infliximab infringes on our manufacturing process patents for Remicade,” Janssen told Reuters in a statement.
Samsung Bioepis told Reuters: “We are confident we do not infringe Janssen’s patents …
“We will take all necessary measures against Janssen’s attempts to violate patient rights and deny patient access to effective, lower cost treatment options.”